The mission of Pharmacoanalytical Laboratory (PAL) is to provide intellectual and analytical support to basic, translational and clinical scientists. For basic science investigators, the PAL assists in the development of discoveries from the """"""""test tube"""""""" to potential clinical modalities. Potential anticancer or diagnostic agents derived from laboratory concepts are further developed using in vitro and in vivo models developed with intellectual support from the PAL. For clinicians, the PAL provides analytical and pharmacokinetic/pharmacodynamics support to further understand the underlying mechanisms that may influence clinical outcome. In an effort to meet these needs, the PAL has acquired the capacity to develop specific analytical and biologically-based techniques to support basic, translational and clinically-based efforts. This includes the development of highly sensitive quantification methods by using ELISA- and liquid chromatography tandem mass spectrometry (LC-MS/MS)-based technology. LC-MS/MS-based technology can minimize the amount of sample volume required, thus allowing serial drug analysis in pediatric populations and even in small animals. In addition, the PAL has developed methods using LC-MS/MS to determine intracellular concentration nucleosides and their anabolites that include the activated component, the triphosphate nucleotides. These techniques can also be used to analyze intracellular nucleotide pools to study cellular mechanisms that lead to nucleoside resistance. In addition, the PAL collaborates in the design of clinical protocols having a pharmacokinetic component and evaluates the results of human pharmacokinetic studies. Despite these developments, the PAL has maintained and enhanced its core analytical capacity using HPLC-based assays utilizing UV and fluorescence detection. These assays are reliable analytical capabilities that can support clinical protocols that mandate drug level determinations. The PAL fosters an environment to enhance collaboration between basic, translational and clinical scientists.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-35
Application #
8056489
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-12-01
Budget End
2010-11-30
Support Year
35
Fiscal Year
2010
Total Cost
$147,914
Indirect Cost
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Guo, Hao; Lee, Changrim; Shah, Mihir et al. (2018) A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. J Control Release 292:183-195
Peddi, Santosh; Pan, Xiaoli; MacKay, John Andrew (2018) Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis. Front Pharmacol 9:1184
Zhao, Yi; Wu, Kaijin; Wu, Yongfeng et al. (2018) Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists. Curr Mol Pharmacol 11:113-121
Kahn, Michael (2018) Wnt Signaling in Stem Cells and Cancer Stem Cells: A Tale of Two Coactivators. Prog Mol Biol Transl Sci 153:209-244
Park, Sungshim L; Patel, Yesha M; Loo, Lenora W M et al. (2018) Association of internal smoking dose with blood DNA methylation in three racial/ethnic populations. Clin Epigenetics 10:110
Liu, Jie; Liang, Gangning; Siegmund, Kimberly D et al. (2018) Data integration by multi-tuning parameter elastic net regression. BMC Bioinformatics 19:369
McDonnell, Kevin J; Chemler, Joseph A; Bartels, Phillip L et al. (2018) A human MUTYH variant linking colonic polyposis to redox degradation of the [4Fe4S]2+ cluster. Nat Chem 10:873-880
Schirripa, Marta; Zhang, Wu; Yang, Dongyun et al. (2018) NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS One 13:e0193640

Showing the most recent 10 out of 842 publications